These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 19860840)
1. Gene silencing of glypican-3 in clear cell carcinoma of the ovary renders it more sensitive to the apoptotic agent paclitaxel in vitro and in vivo. Umezu T; Shibata K; Shimaoka M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Senga T; Kikkawa F Cancer Sci; 2010 Jan; 101(1):143-8. PubMed ID: 19860840 [TBL] [Abstract][Full Text] [Related]
2. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells. Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957 [TBL] [Abstract][Full Text] [Related]
3. Downregulation of glypican-3 expression increases migration, invasion, and tumorigenicity of human ovarian cancer cells. Liu Y; Zheng D; Liu M; Bai J; Zhou X; Gong B; Lü J; Zhang Y; Huang H; Luo W; Huang G Tumour Biol; 2015 Sep; 36(10):7997-8006. PubMed ID: 25967456 [TBL] [Abstract][Full Text] [Related]
4. Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary. Umezu T; Shibata K; Kajiyama H; Yamamoto E; Nawa A; Kikkawa F J Clin Pathol; 2010 Nov; 63(11):962-6. PubMed ID: 20972242 [TBL] [Abstract][Full Text] [Related]
5. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma. Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581 [TBL] [Abstract][Full Text] [Related]
6. Rapamycin inhibits lung squamous cell carcinoma growth by downregulating glypican-3/Wnt/β-catenin signaling and autophagy. Bi Y; Jiang Y; Li X; Hou G; Li K J Cancer Res Clin Oncol; 2021 Feb; 147(2):499-505. PubMed ID: 33225417 [TBL] [Abstract][Full Text] [Related]
8. Suppression of glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGF-β2. Sun CK; Chua MS; He J; So SK Neoplasia; 2011 Aug; 13(8):735-47. PubMed ID: 21847365 [TBL] [Abstract][Full Text] [Related]
9. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells. Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057 [TBL] [Abstract][Full Text] [Related]
10. GPC3 expression in mouse ovarian cancer induces GPC3‑specific T cell-mediated immune response through M1 macrophages and suppresses tumor growth. Luo C; Shibata K; Suzuki S; Kajiyama H; Senga T; Koya Y; Daimon M; Yamashita M; Kikkawa F Oncol Rep; 2014 Sep; 32(3):913-21. PubMed ID: 24992906 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Peters MG; Farías E; Colombo L; Filmus J; Puricelli L; Bal de Kier Joffé E Breast Cancer Res Treat; 2003 Jul; 80(2):221-32. PubMed ID: 12908826 [TBL] [Abstract][Full Text] [Related]
12. Oncofetal protein glypican-3 distinguishes yolk sac tumor from clear cell carcinoma of the ovary. Esheba GE; Pate LL; Longacre TA Am J Surg Pathol; 2008 Apr; 32(4):600-7. PubMed ID: 18277882 [TBL] [Abstract][Full Text] [Related]
13. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Kandil DH; Cooper K Adv Anat Pathol; 2009 Mar; 16(2):125-9. PubMed ID: 19550373 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of glypican-3 expression via RNA interference influences the growth and invasive ability of the MHCC97-H human hepatocellular carcinoma cell line. Ruan J; Liu F; Chen X; Zhao P; Su N; Xie G; Chen J; Zheng D; Luo R Int J Mol Med; 2011 Oct; 28(4):497-503. PubMed ID: 21617840 [TBL] [Abstract][Full Text] [Related]
15. Silencing of the glypican-3 gene affects the biological behavior of human hepatocellular carcinoma cells. Qi XH; Wu D; Cui HX; Ma N; Su J; Wang YT; Jiang YH Mol Med Rep; 2014 Dec; 10(6):3177-84. PubMed ID: 25270552 [TBL] [Abstract][Full Text] [Related]
16. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports. Suzuki S; Shibata K; Kikkawa F; Nakatsura T Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799 [TBL] [Abstract][Full Text] [Related]
17. Inactivation of Wnt signaling by a human antibody that recognizes the heparan sulfate chains of glypican-3 for liver cancer therapy. Gao W; Kim H; Feng M; Phung Y; Xavier CP; Rubin JS; Ho M Hepatology; 2014 Aug; 60(2):576-87. PubMed ID: 24492943 [TBL] [Abstract][Full Text] [Related]
18. Silencing glypican-3 expression induces apoptosis in human hepatocellular carcinoma cells. Liu S; Li Y; Chen W; Zheng P; Liu T; He W; Zhang J; Zeng X Biochem Biophys Res Commun; 2012 Mar; 419(4):656-61. PubMed ID: 22382024 [TBL] [Abstract][Full Text] [Related]
19. Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells. Wichert A; Stege A; Midorikawa Y; Holm PS; Lage H Oncogene; 2004 Jan; 23(4):945-55. PubMed ID: 14661052 [TBL] [Abstract][Full Text] [Related]
20. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma. Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]